GlassScriptPhysician profile
Michael T Lipcan
NPI 1770624447
$6,642.29
in general payments reported to CMS, 2019-2025
31 companies · $874 in 2025
The $874 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,721 · 2020: $414 · 2021: $1,575 · 2022: $2,059 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $873.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,334.37 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,144.18 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $1,055.65 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $519.44 | 2019-2025 | Tremfya |
| Gilead Sciences, INC. | $460.27 | 2019-2025 | |
| Celgene Corporation | $338.12 | 2021-2022 | |
| Qol Medical, LLC | $309.03 | 2021-2025 | Sucraid |
| Ferring Pharmaceuticals INC. | $139.80 | 2019-2022 | |
| Braintree Laboratories, INC. | $139.15 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $138.58 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $122.05 | 2019-2022 | |
| Pfizer INC. | $101.93 | 2019-2025 | |
| Ardelyx, INC. | $100.74 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $89.02 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $67.67 | 2025 | Voquezna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $67.59 | 2019 | |
| Aimmune Therapeutics, INC. | $63.43 | 2025 | Zenpep |
| Ucb, INC. | $55.99 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $53.28 | 2022 | |
| Nestle Healthcare Nutrition INC. | $52.12 | 2022 | |
| Genzyme Corporation | $49.25 | 2022 | |
| Daiichi Sankyo INC. | $45.61 | 2019-2021 | |
| Exact Sciences Corporation | $31.37 | 2025 | The Cologuard Plus Collection Kit |
| Endo Pharmaceuticals INC. | $27.65 | 2019-2021 | |
| Lilly USA, LLC | $26.36 | 2025 | Omvoh |
| Evoke Pharma, INC. | $24.61 | 2022 | |
| Intercept Pharmaceuticals, INC. | $21.20 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.31 | 2022 | |
| Redhill Biopharma INC. | $16.44 | 2021 | |
| Shire North American Group INC | $15.93 | 2019 | |
| Alfasigma USA, INC. | $12.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lipcan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.